Mildred Mosler Weisenfeld is the Brooklyn-born founder of national not-for-profit foundation the National Council to Combat Blindness in 1946, now known as Fight for Sight, an organization based in New York City that provides initial funds to promising scientists early in their careers. For 50 years, Weisenfeld was a one-woman campaign to increase funding for eye research, despite losing her own vision and having no scientific training.
Background
At age 15, Weisenfeld began to lose her vision to degenerative eye diseaseretinitis pigmentosa. Although she completed high school and went on to Brooklyn College, her eyesight worsened and her treatment options were few despite visiting more than 100 specialists in the U.S. and Europe. Weisenfeld was surprised to find that most eye and vision funding went into care for the blind rather than treatments or research. As she continued to search for treatment, she was urged by many of the eye specialists to encourage funding of research for eye disease, which totaled just a few thousand annually around World War II. By age 23, her sight was completely lost. In 1946, 10 years after she was diagnosed with retinitis pigmentosa, Weisenfeld founded the National Council to Combat Blindness, New York, at age 25 with $8 and no office. Addressing how other nonprofits focused on adjusting people to their condition of vision problems, Weisenfeld was quoted May 23, 1948, in the New York Mirror as saying "something must be done beyond giving them a dog, a cane, or a Braille book. We must give those who need it the hope that science is actively probing the affliction robbing them of their sight." Weisenfeld herself never learned Braille or used a cane or a guide dog. Known for her audacity, Weisenfeld helped put vision research on the national agenda when she coordinated testimony on eye research before the House in 1949, which led Congress to recognize eye disease and create the National Institute of Neurological Disease and Blindness, and the 1968 establishment of the National Eye Institute in the National Institutes of Health. Over the decades as Fight for Sight's executive director, Weisenfeld paid herself no salary and tirelessly worked six- or seven-day weeks to raise millions of dollars for research and launch the careers of many prominent vision researchers through Fight for Sight and its local women's leagues in New York, Northern NJ, Pennsylvania and Florida. Fight for Sight celebrates its 65th anniversary in 2011.
, who became honorary chairman of her organization, helped attract many notable celebrities for the annual "Lights On" fundraiser and donated $100,000 in 1960 to establish the Bob Hope Fight for Sight Fund. Focusing partly on children, up to eight clinics carried the name of Weisenfeld's organization from combined donations exceeding $13 million. They were the Fight for Sight Children's Eye Centers in New York, Miami, two in Pittsburgh, Philadelphia, and Newark, NJ.
Honors
Many honors were bestowed upon Weisenfeld in tribute to her lifelong work. In 1951, Weisenfeld was presented with the Eleanor Roosevelt Award for community service. On the 25th anniversary of Fight for Sight in 1971, President Richard Nixon and New York City MayorJohn Lindsay recognized Weisenfeld's work with congratulatory letters. In 1975, the Academy of Ophthalmology awarded Weisenfeld its first award given to a lay person, for her contributions to the field. The industry group ARVO established the Weisenfeld Award for Excellence in Ophthalmology in 1986, to recognize individuals for scholarly contributions to clinical ophthalmology. On Fight for Sight's 50th anniversary, Weisenfeld received the Lighthouse Pisart Vision Award in 1996 for her leadership and accomplishments. In 2000, Columbia University's Harkness Eye Institute Children's Diagnostic Clinic was renamed the Fight for Sight/Mildred Weisenfeld Children's Diagnostic Clinic. Fight for Sight was led by Weisenfeld for 50 years, until she fell into ill health in 1996. An avid smoker, Weisenfeld died a year later at age 76 from complications of lung cancer.